OS Therapies
NYSE: OSTXGrasonville, US · Founded 2018 · Delaware corporation · 2 known investors
Founders & leadership
CP
Christopher P. AcevedoinChief Financial Officer
RG
Robert G. PetitinChief Medical Officer and Chief Scientific Officer
GC
Gerald CommissionginChief Business Officer
PR
Paul RomnessinCEO
Board
JC
John CiccioBoard director
TF
Theodore F. SearchBoard director
OR
Olivier R. JarryBoard director
AM
Avril McKean DieserBoard director
CE
Craig EagleBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$31.3M disclosed across 11 of 12 rounds · 2018–2026
▶$5MraisedAug 2026 · 10 investors · BiotechnologyRule 506(b)
▶$5MraisedAug 2026 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul A. RomnessExecutive Officer, Director
- Robert G. PetitExecutive Officer
- Christopher P. AcevedoExecutive Officer
- John CiccioDirector
- Avril McKean DieserDirector
- Craig EagleDirector
- Olivier JarryDirector
- Theodore F. SearchDirector
- Offering amount
- $10M
- Amount sold
- $5M
- Sales commissions
- $500K
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedJul 2026 · 1 investors · BiotechnologyRule 506(b)
▶$1.6MraisedJul 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul A. RomnessExecutive Officer, Director
- Robert G. PetitExecutive Officer
- Christopher P. AcevedoExecutive Officer
- John CiccioDirector
- Avril McKean DieserDirector
- Craig EagleDirector
- Olivier JarryDirector
- Theodore F. SearchDirector
- Offering amount
- $9.3M
- Amount sold
- $1.6M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedMar 2026 · 9 investors · BiotechnologyRule 506(b)
▶$2MraisedMar 2026 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Theodore F. SearchDirector
- Paul A. RomnessExecutive Officer, Director
- Karim GalzahrDirector
- Olivier JarryDirector
- Christopher P. AcevedoExecutive Officer
- John CiccioDirector
- Avril McKean DieserDirector
- Robert G. PetitExecutive Officer
- Offering amount
- $2M
- Amount sold
- $2M
- Sales commissions
- $140K
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedJan 2026 · 9 investors · BiotechnologyRule 506(b)
▶$3.5MraisedJan 2026 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John CiccioDirector
- Avril McKean DieserDirector
- Olivier JarryDirector
- Christopher P. AcevedoExecutive Officer
- Theodore F. SearchDirector
- Robert G. PetitExecutive Officer
- Karim GalzahrDirector
- Paul A. RomnessExecutive Officer, Director
- Offering amount
- $7.5M
- Amount sold
- $3.5M
- Sales commissions
- $627.5K
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.8MraisedSep 2025 · 10 investors · BiotechnologyRule 506(b)
▶$3.8MraisedSep 2025 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul A. RomnessExecutive Officer, Director
- Avril McKean DieserDirector
- Christopher P. AcevedoExecutive Officer
- Karim GalzahrDirector
- Robert G. PetitExecutive Officer
- John CiccioDirector
- Theodore F. SearchDirector
- Olivier JarryDirector
- Offering amount
- $3.8M
- Amount sold
- $3.8M
- Sales commissions
- $56.7K
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedJul 2025 · 27 investors · BiotechnologyRule 506(b)
▶$4.2MraisedJul 2025 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John CiccioDirector
- Olivier JarryDirector
- Karim GalzahrDirector
- Paul A. RomnessExecutive Officer, Director
- Robert G. PetitExecutive Officer
- Christopher P. AcevedoExecutive Officer
- Theodore F. SearchDirector
- Avril McKean DieserDirector
- Offering amount
- $4.2M
- Amount sold
- $4.2M
- Sales commissions
- $210.8K
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.1MraisedJan 2025 · 34 investors · PharmaceuticalsRule 506(b)
▶$7.1MraisedJan 2025 · 34 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Avril McKean DieserDirector
- John CiccioDirector
- Christopher P. AcevedoExecutive Officer
- Theodore F. SearchDirector
- Paul A. RomnessExecutive Officer, Director
- Robert G. PetitExecutive Officer
- Gerald CommissiongExecutive Officer
- Olivier R. JarryDirector
- Offering amount
- $10M
- Amount sold
- $7.1M
- Minimum investment
- $10K
- Sales commissions
- $240K
- Placement agents
- Arcadia Securities, LLC, Ceros Financial Services, Inc.
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$700KraisedDec 2023 · 3 investors · BiotechnologyRule 506(b)
▶$700KraisedDec 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul A. RomnessExecutive Officer, Director
- Colin GoddardDirector
- Theodore F. SearchDirector
- Joacim BorgDirector
- Christopher P. AcevedoExecutive Officer
- Robert G. PetitExecutive Officer
- John CiccioDirector
- Offering amount
- $2M
- Amount sold
- $700K
- Minimum investment
- $50K
- Sales commissions
- $70K
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Robinhood20 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits17 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Artios Pharma16 shared keywordsArtios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers. The company focuses on advancing DDR-based therapies through strategic partnerships.
Seeking Alpha15 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with OS Therapies for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
OS Therapies sets $75M ATM stock program with Jefferies | OSTX 8-K Filingstocktitan.net · Aug 2026
OS Therapies Ends At-The-Market Equity Sales Program - TipRanks.comtipranks.com · Jul 2026
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update - BioSpacebiospace.com · May 2026Frequently asked questions
- Who are OS Therapies's investors?
- OS Therapies's investors include K20 Fund, Jefferies.
- How much funding has OS Therapies raised?
- OS Therapies has disclosed $31.3M raised across 11 of its 12 known rounds.
- Where is OS Therapies headquartered?
- OS Therapies is headquartered in Grasonville, US.